We became the first pharma company in Asia outside Japan to list on the New York Stock Exchange.
We went public on the Bombay Stock Exchange and launched APIs in India. In the 1980s, we were among the first to export APIs to the USA.
Our first pioneering mega-brand Omez (Omeprazole) was launched in India, becoming our first 100 crore brand and a leader in Indian pharma.
We expanded our operations internationally by opening a branch in Russia.
Dr. Anji Reddy founded the Dr. Reddy’s Foundation to give back to society. Our CSR activities include health, education, livelihood, and sustainability.
We were the first Indian pharma company to out-license a novel drug to an innovator.
We became the first pharma company in Asia outside Japan to list on the New York Stock Exchange.
We became the first pharma company in Asia outside Japan to list on the New York Stock Exchange.
Our founder, Dr. Anji Reddy, received the Padma Shri from the Gov’t of India.
Aurigene Oncology Ltd, our Bengaluru subsidiary, was incorporated for drug discovery.
We released our first Safety, Health, Environment (SHE) report. We were also among the earliest to initiate annual voluntary sustainability disclosures from the following year.
We became the first Indian pharma company to launch an Authorized Generic (AG) in the U.S. (nasteride 5 mg, generic equivalent of Merck’s Proscar tabs 5 mg).
We became the fastest Indian pharma company to cross USD 1 billion in revenue.
We launched the world’s then first monoclonal antibody biosimilar of rituximab in India (Reditux).
We launched the world’s then first monoclonal antibody biosimilar of rituximab in India (Reditux).
We adopted 6 sustainability goals for the next decade.
Our founder, Dr. Anji Reddy, was honoured with the Padma Bhushan by the Gov’t of India for his contribution to the Indian pharma industry.
Acquired a select portfolio of Belgium based UCBs established brands in certain South Asian countries
We were listed on the Dow Jones Sustainability Index 2016 for Emerging Markets.
We entered the branded consumer health arena through the acquisition of six OTC brands from Ducere Pharma.
We entered the nutrition segment in India with the launch of Celevida, a first-of-its-kind product in Dr. Reddy’s nutrition portfolio.
We were the first foreign generics company to get approval to supply Olanzapine to China's public hospitals under the QCE system.
We became the first company in India and third in Asia
to join the Science-Based targets initiative (SBTi).
We acquired select divisions of Wockhardt in India.
Our focus on agility, access and affordability helped us
reach over 5 million patients during the pandemic,
especially in low and middle income countries.
We combined in-house efforts with open-innovation
partnerships to provide a portfolio that included a vaccine and therapeutics for COVID-19.
Our company played its part along with the rest of
the pharma industry in the fight against COVID-19.
Launched Lenalidomide capsule in the U.S., with two of the six strengths eligible for first-to-market, 180-day exclusivity
Our Hyderabad facility was recognised by the World Economic Forum as part of its Global Lighthouse Network for Industry 4.0 leadership.
We were named by the prestigious Science Magazine
as among the Top 20 employers globally in pharma/biotech. We acquired medical cannabis company, Nimbus Health GmbH, in Germany.
Dr. Reddy's Foundation received a National Award from the President of India for the Empowerment of Persons with Disabilities.
We became the first Indian pharma company to debut on the Dow Jones Sustainability World Index.
We launched Nerivio® in India for migraine management.
Our platform ‘Celevida Wellness’ became our first D2C
e-commerce platform in India carrying our products for
diabetes nutrition and third-party brands.
Our proposed rituximab biosimilar dossier was accepted for review by the USFDA, MHRA and EMA.
We entered into strategic collaborations for novel
molecules - with the U.S.-based Coya Therapeutics for
a novel combination biologic for ALS; with China-based
Junshi Biosciences for Toripalimab; and with Jiangsu
Hengrui for Pyrotinib.
We were included in the Bloomberg Gender-Equality Index for the 6th year in a row.
Partnered with Nestle India to launch nutritional health
solutions in India and other regions
Acquired Menolabs' women's health and dietary
supplements portfolio from Amyris Inc. including seven
products for perimenopause and menopause support
Signed a definitive agreement with Haleon Plc to acquire Nicotinell and its Nicotine Replacement Therapy portfolio